CliffBio
biologic

Benefix

Coagulation Factor IX (Recombinant)

Loss of exclusivityMarch 2019projected — 12-year biologic exclusivity estimate
CompanyWyeth →See this company's full patent-cliff portfolio

Drug detail

Brand nameBenefix
Active ingredientCoagulation Factor IX (Recombinant)
Strength2000IU/ML
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalMarch 2007
Marketing statusRx

More from Wyeth

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Benefix patent cliff — loss of exclusivity March 2019 | CliffBio